2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by DOUCET, C. Articles by THILLET, J. Search for Related Content PubMed PubMed Citation Articles by DOUCET, C. Articles by THILLET, J.

Lipoprotein(a) in the Nephrotic Syndrome

Molecular Analysis ofLipoprotein(a) and Apolipoprotein(a) Fragments in Plasma and Urine

CHANTAL DOUCET^*, VINCENT MOOSER, SOPHIE GONBERT^*, FRANÇOISE RAYMOND, JOHN CHAPMAN^*, CLAUDE JACOBS and JOËLLE THILLET^*

^* Institut National de la Santé et de la Recherche Médicale, Unité 321, Paris Cedex, France
Service de Néphrologie, Hôpital de la Pitié, Paris Cedex, France
Department of Internal Medicine B, Lausanne University Hospital, CHUV-Lausanne, Switzerland.

Correspondence to Dr. Joëlle Thillet, Institut National de la Santé et de la Recherche Médicale, Unité 321, "Lipoprotéines et Athérogénèse". Hôpital de la Pitié, 83 Boulevard de l'Hôpital, 75651 Paris Cedex 13, France. Phone: 01 42 17 78 78; Fax: 01 45 82 81 98; E-mail: thillet{at}ext.jussieu.fr

Abstract. Plasma levels of lipoprotein(a) (Lp(a)), an atherogenic particle, are elevated in kidney disease, which suggests a role of this organ in the metabolism of Lp(a). Additional evidence for a role of the kidney in the clearance of Lp(a) is provided by the fact that circulating N-terminal fragments of apolipoprotein(a) (apo(a)) are processed and eliminated by the renal route. To further understand the mechanism underlying such renal excretion, the levels of apo(a) fragments in plasma and urine relative to plasma Lp(a) levels were determined in patients with nephrotic syndrome (n = 15). In plasma, the absolute (24.7 ± 20.4 versus 2.16 ± 2.99 µg/ml, P < 0.0001) as well as the relative amounts of apo(a) fragments (4.6 ± 3.4% versus 2.1 ± 3.3% of total Lp(a), P < 0.0001) were significantly elevated in nephrotic patients compared with a control, normolipidemic population. In addition, urinary apo(a) excretion in patients with nephrotic syndrome was markedly elevated compared with that in control subjects (578 ± 622 versus 27.7 ± 44 ng/ml per mg creatinine, P < 0.001). However, the fractional catabolic rates of apo(a) fragments were similar in both groups (0.68 ± 0.67% and 0.62 ± 0.47% in nephrotic and control subjects, respectively), suggesting that increased plasma concentrations of apo(a) fragments in nephrotic subjects are more dependent on the rate of synthesis rather than on the catabolic rate. Molecular analysis of apo(a) immunoreactive material in urine revealed that the patterns of apo(a) fragments in nephrotic patients were distinct from those of control subjects. Full-length apo(a), large N-terminal apo(a) fragments similar in size to those present in plasma, as well as C-terminal fragments of apo(a) were detected in urine from nephrotic patients but not in urine from controls. All of these apo(a) forms were in addition to smaller N-terminal apo(a) fragments present in normal urine. This study also demonstrated the presence of Lp(a) in urine from nephrotic patients by ultracentrifugal fractionation. These data suggest that in nephrotic syndrome, Lp(a) and large fragments of apo(a) are passively filtered by the kidney through the glomerulus, whereas smaller apo(a) fragments are secreted into the urine.

This article has been cited by other articles:

				W. J. Cain, J. S. Millar, A. S. Himebauch, U. J. F. Tietge, C. Maugeais, D. Usher, and D. J. Rader Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a] J. Lipid Res., December 1, 2005; 46(12): 2681 - 2691. [Abstract] [Full Text] [PDF]

				M. Ozata, C. Oktenli, M. Gulec, T. Ozgurtas, F. Bulucu, K. Caglar, N. Bingol, A. Vural, and I. C. Ozdemir Increased Fasting Plasma Acylation-Stimulating Protein Concentrations in Nephrotic Syndrome J. Clin. Endocrinol. Metab., February 1, 2002; 87(2): 853 - 858. [Abstract] [Full Text] [PDF]

				S. Gonbert, B. Saint-Jore, P. Giral, C. Doucet, J. Chapman, and J. Thillet Molecular Analysis of Apo(a) Fragmentation in Polygenic Hypercholesterolemia: Characterization of a New Plasma Fragment Pattern Arterioscler. Thromb. Vasc. Biol., August 1, 2001; 21(8): 1353 - 1358. [Abstract] [Full Text] [PDF]

				B. Garner, A. H. Merry, L. Royle, D. J. Harvey, P. M. Rudd, and J. Thillet Structural Elucidation of the N- and O-Glycans of Human Apolipoprotein(a). ROLE OF O-GLYCANS IN CONFERRING PROTEASE RESISTANCE J. Biol. Chem., June 15, 2001; 276(25): 22200 - 22208. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673